Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
SPP1, BSPI, BNSP, Bone sialoprotein 1, ETA-1, Nephropontin, OPN, Secreted phosphoprotein 1, SPP-1, SPP1/CALPHA1 fusion, Urinary stone protein, Uropontin, Osteopontin, Bone sialoprotein I
(tested or 100% immunogen sequence identity)
Monkey (at least 90% immunogen sequence identity)
IHC - Paraffin
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
Synthetic peptide corresponding to amino acids 75-90 (PSKSNESHDHMDDMDD) of human osteopontin, Accession # P10451. Percent identity by BLAST analysis: Human (100%); Gorilla, Orangutan, Gibbon, Monkey (94%); Marmoset, Mouse, Rat (88%); Horse, Rabbit (81%).
Recognizes human osteopontin. No cross-reactivity with human osteonectin or human bone sialoprotein II.
Suitable for use in ELISA and Immunohistochemistry. ELISA: 1:1000. Immunohistochemistry (paraffin-embedded sections): 1:5000. Positive control: Human urine or breast milk (2-5 ug/ml normal concentration).
Binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction.Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity.